课题基金 / 基金详情

Clinical Core

Clinical Core
临床核心
批准号:
10200784
负责人:
LISA Allyn BOARDMAN
金额:
$25.1万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-01 至 2024-06-30

项目摘要

项目成果

LISA Allyn BOARDMAN的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要:临床核心 C-Sig临床核心的目标是提供用户友好的一站式服务,以访问消化系统 为中心成员提供与疾病相关的生物制品。在丽莎·博德曼博士的指导下,一口井- 拥有IRB和生物库专业知识的资深临床医生科学家、 C-Sig临床核心提供必要的专业知识和人员来为C-Sig成员提供建议和互动 追求两个具体目标:第一,集中和加快C-SIG成员获得GI生物检疫制剂的速度。 第二,加强在临床核心架构内运作的现有个别与胃肠病有关的生物库,以及 开发新的存储库。为了实现这些目标,C-Sig临床核心:i)整合了现有的组织集合 并将带注释的数据整合到基于Web的协作组织结构中,C-Sig可以轻松访问该组织结构 成员;二)通过机构内部生物圈计划/生物检疫委员会的批准并协调优先事项 C-Sig成员可获得专业的壁内生物检疫处理服务;以及三)便利 启动新的生物库,重点关注目前尚未收集到的新疾病或类型的生物检疫库 现有生物库,包括开发新的C-Sig生物库,以及四)开发和实施 支持与消化疾病相关的生物库工作的软件工具。核心集成了现有的 资源来自胃肠病和肝病学部的个人研究人员和 机构生物库,为协作翻译GI提供了一种经济高效的方法 进入人体组织的信号范例。此外,C-Sig临床核心已经发展得很强大 与IRB的伙伴关系,解剖病理学冰冻切片实验室(又名TRIG;所有外科手术的来源 生物显微镜)和病理学研究核心(进行组织切片、免疫染色、 等)。这些合作伙伴关系使C-Sig临床核心人员能够加快方案和项目的进展 通过这些关键的机构资源。C-Sig临床核心提供的主要服务是IRB 方案开发支持,生物标本请求支持(包括识别适当的组织, 病理检查和协调组织处理)和生物库支持服务(IRB协议模板, 组织库存管理软件,标准化问卷,每天搜索手术清单 从外科手术和/或内窥镜检查程序中获得的潜在生物检疫制剂, 和有限的研究协调员对同意的支持)。为了回应C-Sig成员的反馈,我们已经 最近增加了支持人类微生物组研究粪便收集的服务,并正在开发中 一条与有机化合物相关的服务线。C-Sig临床核心服务已被54%的当前 中心成员,并在过去4.5年中支持了96种出版物。
英文摘要
PROJECT SUMMARY: CLINICAL CORE The objective of the C-SiG Clinical Core is to provide a user-friendly, one-stop service to access digestive disease-related biospecimens for Center members. Under the direction of Dr. Lisa Boardman, a well- established clinician scientist with IRB and biobanking expertise, the organization and infrastructure of the C-SiG Clinical Core provides essential expertise and personnel to advise and interact with C-SiG members in pursuit of two Specific Aims: First, to centralize and expedite access to GI biospecimens for C-SiG members. Second, to enhance existing individual GI-related biobanks operating within the Clinical Core umbrella and develop new repositories. To achieve these aims C-SiG Clinical Core: i) Integrates existing tissue collections and annotated data into a collaborative web-based organizational structure that is easily accessible by C-SiG members; ii) Expedites institutional IRB protocol/biospecimens committee approval and coordinates priority access for C-SiG members to expert intramural biospecimens processing services; and iii) Facilitates the initiation of new biobanks that will focus on new diseases or types of biospecimens not currently collected by existing biobanks, including the development of the new C-SiG Biobank, and iv) Develops and implements software tools that support digestive disease-related biobank endeavors. The Core integrates existing resources from individual investigators in the Division of Gastroenterology and Hepatology and from institutional biospecimens repositories, providing a cost-effective approach to collaboratively translate GI signaling paradigms into human tissues. Additionally, the C-SiG Clinical Core has developed strong partnerships with the IRB, anatomic pathology frozen section laboratories (aka TRAG; source of all surgical biospecimens), and the Pathology Research Core (facility that performs tissue sectioning, immunostaining, etc.). These partnerships allow C-SiG Clinical Core personnel to expedite movement of protocols and projects through these key institutional resources. The primary services offered by the C-SiG Clinical Core are IRB protocol development support, biospecimens request support (including identification of appropriate tissues, pathology review, & coordinating tissue processing), and biobank support services (IRB protocol templates, tissue inventory management software, standardized questionnaires, daily searches of the surgical list for potential biospecimens to be acquired from surgical and/or endoscopy procedures for approved IRB protocols, and limited study coordinator support for consenting). In response to C-SiG member feedback, we have recently added services to support the collection of stool for human microbiome research and are developing an organoid-related service line. The C-SiG Clinical Core services have been used by 54% of the current Center members and have supported 96 publications in the past 4.5 years.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Epigenetic mechanisms of carcinogenesis by Parvimonas micra, an oral cavity commensal turned colon cancer pathogen
  • 批准号:
    10693952
  • 项目类别:
  • 资助金额:
    $59.39万
  • 财政年份:
    2021
  • 负责人:
    LISA Allyn BOARDMAN
  • 依托单位:
Individualizing colorectal cancer patient care using the host and tumor telomere phenotype
  • 批准号:
    9078116
  • 项目类别:
  • 资助金额:
    $63.61万
  • 财政年份:
    2016
  • 负责人:
    LISA Allyn BOARDMAN
  • 依托单位:
Individualizing colorectal cancer patient care using the host and tumor telomere phenotype
  • 批准号:
    9565504
  • 项目类别:
  • 资助金额:
    $65.8万
  • 财政年份:
    2016
  • 负责人:
    LISA Allyn BOARDMAN
  • 依托单位:
Time lapse to cancer: defining transition from polyp to colorectal cancer (PQ14)
  • 批准号:
    8383183
  • 项目类别:
  • 资助金额:
    $65.41万
  • 财政年份:
    2012
  • 负责人:
    LISA Allyn BOARDMAN
  • 依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
  • 批准号:
    2021JJ40433
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2021
  • 负责人:
    孙磊
  • 依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
  • 批准号:
    32001603
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    段真珍
  • 依托单位:
AREA国际经济模型的移植.改进和应用
  • 批准号:
    18870435
  • 项目类别:
    面上项目
  • 资助金额:
    2.0万元
  • 批准年份:
    1988
  • 负责人:
    史树中
  • 依托单位: